Continuous renal replacement therapy and extended indications.
Journal
Seminars in dialysis
ISSN: 1525-139X
Titre abrégé: Semin Dial
Pays: United States
ID NLM: 8911629
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
02
02
2021
received:
26
11
2020
accepted:
08
02
2021
pubmed:
13
3
2021
medline:
15
3
2022
entrez:
12
3
2021
Statut:
ppublish
Résumé
Extracorporeal blood purification (EBP) techniques provide support for critically ill patients with single or multiple organ dysfunction. Continuous renal replacement therapy (CRRT) is the modality of choice for kidney support for those patients and orchestrates the interactions between the different artificial organ support systems. Intensive care teams should be familiar with the concept of sequential extracorporeal therapy and plan on how to incorporate new treatment modalities into their daily practices. Importantly, scientific evidence should guide the decision-making process at the bedside and provide robust arguments to justify the costs of implementing new EBP treatments. In this narrative review, we explore the extended indications for CRRT as an adjunctive treatment to provide support for the heart, lung, liver, and immune system. We detail practicalities on how to run the treatments and how to tackle the most frequent complications regarding each of the therapies, whether applied alone or integrated. The physicochemical processes and technologies involved at the molecular level encompassing the interactions between the molecules, membranes, and resins are spotlighted. A clinical case will illustrate the timing for the initiation, maintenance, and discontinuation of EBP techniques.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
550-560Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Ronco C. Continuous renal replacement therapy: forty-year anniversary. Int J Artif Organs. 2017;40(6):257-264.
Ankawi G, Neri M, Zhang J, Breglia A, Ricci Z, Ronco C. Extracorporeal techniques for the treatment of critically ill patients with sepsis beyond conventional blood purification therapy: the promises and the pitfalls. Crit Care. 2018;22(1):262.
Wendon J, Cordoba J, Dhawan A, et al. EASL clinical practical guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66(5):1047-1081.
Redant S, De Bels D, Barbance O, Loulidi G, Honoré PM. Extracorporeal CO2 removal integrated within a continuous renal replacement circuit offers multiple advantages. Blood Purif. 2020;50(1):1-8.
Matthay MA, Zemans RL, Zimmerman GA, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019;5(1):18.
Menk M, Estenssoro E, Sahetya SK, et al. Current and evolving standards of care for patients with ARDS. Intensive Care Med. 2020. https://doi.org/10.1007/s00134-020-06299-6.
de Chambrun MP, Bréchot N, Combes A. The place of extracorporeal life support in cardiogenic shock. Curr Opin Crit Care. 2020. https://doi.org/10.1097/MCC.0000000000000747
De Rosa S, Samoni S, Ronco C. Sequential extracorporeal therapy collaborative device and timely support for endotoxic, septic, and cardiac shock: a case report. Blood Purif. 2020;;49(4):502-508.
Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2(8):611-620.
Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent J-L. Sepsis and septic shock. Nat Rev Dis Primers. 2016;2(1):16045.
Sarma A, Calfee CS, Ware LB. Biomarkers and precision medicine. Crit Care Clin. 2020;36(1):155-165.
Seymour CW, Kennedy JN, Wang S, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019;321(20):2003.
Wiersema R, Jukarainen S, Vaara ST, et al. Two subphenotypes of septic acute kidney injury are associated with different 90-day mortality and renal recovery. Crit Care. 2020;24(1):150.
Leligdowicz A, Matthay MA. Heterogeneity in sepsis: new biological evidence with clinical applications. Crit Care. 2019;23(1):80.
Reis T. Acute kidney injury. Rev Assoc Med Bras. 2020;66(suppl 1):s68-s74.
Shiga H, Hirasawa H, Nishida O, et al. Continuous hemodiafiltration with a cytokine-adsorbing hemofilter in patients with septic shock: a preliminary report. Blood Purif. 2014;38(3-4):211-218.
Terragni PP, Del Sorbo L, Mascia L, et al. Tidal volume lower than 6 ml/kg enhances lung protection. Anesthesiology. 2009;111(4):826-835.
Morales-Quinteros L, Camprubí-Rimblas M, Bringué J, Bos LD, Schultz MJ, Artigas A. The role of hypercapnia in acute respiratory failure. Intensive Care Med Exp. 2019;7(S1):39.
Morales-Quinteros L, Del Sorbo L, Artigas A. Extracorporeal carbon dioxide removal for acute hypercapnic respiratory failure. Ann Intensive Care. 2019;9(1):79.
Wang Y, Bellomo R. Cardiac surgery-associated acute kidney injury: risk factors, pathophysiology and treatment. Nat Rev Nephrol. 2017;13(11):697-711.
Nadim MK, Forni LG, Bihorac A, et al. Cardiac and vascular surgery-associated acute kidney injury: the 20th International Consensus Conference of the ADQI (Acute Disease Quality Initiative) Group. JAHA. 2018;7(11). https://doi.org/10.1161/JAHA.118.008834
de Chambrun MP, Donker DW, Combes A. What's new in cardiogenic shock? Intensive Care Med. 2020;46(5):1016-1019.
Li Y, Yan S, Gao S, et al. Effect of an intra-aortic balloon pump with venoarterial extracorporeal membrane oxygenation on mortality of patients with cardiogenic shock: a systematic review and meta-analysis†. Eur J Cardiothorac Surg. 2019;55(3):395-404.
Combes A, Schmidt M, Hodgson CL, et al. Extracorporeal life support for adults with acute respiratory distress syndrome. Intensive Care Med. 2020. https://doi.org/10.1007/s00134-020-06290-1
Ronco C, Clark WR. Haemodialysis membranes. Nat Rev Nephrol. 2018;14(6):394-410.
Leypoldt JK, Storr M, Agar BU, et al. Intradialytic kinetics of middle molecules during hemodialysis and hemodiafiltration. Nephrol Dial Transplant. 2019;34(5):870-877.
Henrion J. Hypoxic hepatitis. Liver Int. 2012;32(7):1039-1052.
Slack AJ, Auzinger G, Willars C, et al. Ammonia clearance with haemofiltration in adults with liver disease. Liver Int. 2014;34(1):42-48.
Gupta S, Fenves AZ, Hootkins R. The role of RRT in hyperammonemic patients. Clin J Am Soc Nephrol. 2016;11(10):1872-1878.
Cardoso FS, Gottfried M, Tujios S, Olson JC, Karvellas CJ. For the US Acute Liver Failure Study Group. Continuous renal replacement therapy is associated with reduced serum ammonia levels and mortality in acute liver failure. Hepatology. 2018;67(2):711-720.
Raina R, Bedoyan JK, Lichter-Konecki U, et al. Consensus guidelines for management of hyperammonaemia in paediatric patients receiving continuous kidney replacement therapy. Nat Rev Nephrol. 2020;16(8):471-482.
Redant S, Beretta-Piccoli X, Mugisha A, et al. Hyperammonemia, the last indication of high-volume hemodiafiltration in adult and children: a structured review. Blood Purif. 2019;48(4):330-335.
Benyoub K, Muller M, Bonnet A, et al. Amounts of bile acids and bilirubin removed during single-pass albumin dialysis in patients with liver failure: letters to the editor. Ther Apher Dial. 2011;15(5):504-506.
Sponholz C, Matthes K, Rupp D, et al. Molecular adsorbent recirculating system and single-pass albumin dialysis in liver failure-a prospective, randomised crossover study. Crit Care. 2015;20(1):2.
Schmuck RB, Nawrot G-H, Fikatas P, Reutzel-Selke A, Pratschke J, Sauer IM. Single pass albumin dialysis-a dose-finding study to define optimal albumin concentration and dialysate flow: single pass albumin dialysis. Artif Organs. 2017;41(2):153-161.
Viggiano D, de Pascale E, Marinelli G, Pluvio C. A comparison among three different apheretic techniques for treatment of hyperbilirubinemia. J Artif Organs. 2018;21(1):110-116.
El Chediak A, Janom K, Koubar SH. Bile cast nephropathy: when the kidneys turn yellow. Ren Replace Ther. 2020;6(1):15.
Patel J, Walayat S, Kalva N, Palmer-Hill S, Dhillon S. Bile cast nephropathy: A case report and review of the literature. World J Gastroenterol. 2016;22(27):6328.
On behalf of the European Society of Intensive Care Medicine Trials Group and the “Strategy of Ultra-Protective lung ventilation with Extracorporeal CO2 Removal for New-Onset moderate to severe ARDS” (SUPERNOVA) investigators, Combes A, Fanelli V, Pham T, Ranieri VM. Feasibility and safety of extracorporeal CO2 removal to enhance protective ventilation in acute respiratory distress syndrome: the SUPERNOVA study. Intensive Care Med. 2019;45(5):592-600.
Combes A, Auzinger G, Capellier G, et al. ECCO2R therapy in the ICU: consensus of a European round table meeting. Crit Care. 2020;24(1):490.
López-Sánchez M, Rubio-López MI. Extracorporeal carbon dioxide removal with continuous renal replacement therapy. Case description and literature review. Rev Bras Ter Intensiva. 2020;32(1). https://doi.org/10.5935/0103-507X.20200020
Thomas M, Moriyama K, Ledebo I. AN69: evolution of the world's first high permeability membrane. In: Saito A, Kawanishi H, Yamashita AC, Mineshima M, eds. Contributions to Nephrology. Basel, Switzerland: KARGER; 2011:119-129.
Malard B, Lambert C, Kellum JA. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices. Intensive Care Med Exp. 2018;6(1):12.
Monard C, Rimmelé T, Ronco C. Extracorporeal blood purification therapies for sepsis. Blood Purif. 2019;47(3):1-14.
Broman ME, Hansson F, Vincent J-L, Bodelsson M. Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: a randomized crossover double-blind study. PLoS One. 2019;14(8):e0220444.
De Rosa S, Villa G, Ronco C. The golden hour of polymyxin B hemoperfusion in endotoxic shock: the basis for sequential extracorporeal therapy in sepsis. Artif Organs. 2020;44(2):184-186.
Iba T, Fowler L. Is polymyxin B-immobilized fiber column ineffective for septic shock? A discussion on the press release for EUPHRATES trial. J Intensive Care. 2017;5(1):40.
Kim JJ, Park YJ, Moon KY, Park JH, Jeong YK, Kim EY. Polymyxin B hemoperfusion as a feasible therapy after source control in abdominal septic shock. World J Gastrointest Surg. 2019;11(12):422-432.
Klein DJ, Foster D, Walker PM, Bagshaw SM, Mekonnen H, Antonelli M. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med. 2018;44(12):2205-2212.
Dellinger RP, Bagshaw SM, Antonelli M, et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA. 2018;320(14):1455.
Bonavia A, Groff A, Karamchandani K, Singbartl K. Clinical utility of extracorporeal cytokine hemoadsorption therapy: a literature review. Blood Purif. 2018;46(4):337-349.
Kaçar CK, Uzundere O, Kandemir D, Yektaş A. Efficacy of HA330 hemoperfusion adsorbent in patients followed in the intensive care unit for septic shock and acute kidney injury and treated with continuous venovenous hemodiafiltration as renal replacement therapy. Blood Purif. 2020;49(4):448-456.
Chu L, Li G, Yu Y, Bao X, Wei H, Hu M. Clinical effects of hemoperfusion combined with pulse high-volume hemofiltration on septic shock. Medicine (Baltimore). 2020;99(9):e19058.
Stads S, Kant KM, de Jong MFC, et al. Predictors of 90-day restart of renal replacement therapy after discontinuation of continuous renal replacement therapy, a prospective multicenter study. Blood Purif. 2019;48(3):243-252.
Boschetti-de-Fierro A, Voigt M, Storr M, Krause B. MCO membranes: enhanced selectivity in high-flux class. Sci Rep. 2015;5(1):18448.
Boschetti-de-Fierro A, Voigt M, Storr M, Krause B. Extended characterization of a new class of membranes for blood purification: the high cut-off membranes. Int J Artif Organs. 2013;36(7):455-463.
Ronco C. Backfiltration: a controversial issue in modern dialysis. Int J Artif Organs. 1988;11(2):69-74.
Fiore GB, Ronco C. Internal hemodiafiltration (iHDF): a possible option to expand hemodiafiltration therapy. Int J Artif Organs. 2004;27(5):420-423.
Lorenzin A, Neri M, Lupi A, et al. Quantification of internal filtration in hollow fiber hemodialyzers with medium cut-off membrane. Blood Purif. 2018;46(3):196-204.
Ronco C, La Manna G. Expanded hemodialysis: a new therapy for a new class of membranes. In: La Manna G, Ronco C, editors. Contributions to Nephrology. Basel, Switzerland: S. Karger AG; 2017;124-133.
Reis T, Martino F, Dias P, et al. Removal of middle molecules with medium cutoff dialyzer in patients on short frequent hemodialysis. Hemodial Int. 2020. https://doi.org/10.1111/hdi.12906
Ricci Z, Ronco C, Bachetoni A, et al. Solute removal during continuous renal replacement therapy in critically ill patients: convection versus diffusion. Crit Care. 2006;10(2):R67.
Ricci Z, Romagnoli S, Ronco C. Acute kidney injury: to dialyse or to filter? Nephrol Dial Transplant. 2020;35(1):44-46. https://doi.org/10.1093/ndt/gfz022
Hatamizadeh P, Tolwani A, Palevsky P. Revisiting filtration fraction as an index of the risk of hemofilter clotting in continuous venovenous hemofiltration. Clin J Am Soc Nephrol. 2020;15(11):1660-1662.
Ficheux A, Gayrard N, Szwarc I, et al. Measuring intradialyser transmembrane and hydrostatic pressures: pitfalls and relevance in haemodialysis and haemodiafiltration. Clinical Kidney Journal. 2020;13(4):580-586.
Kakajiwala A, Jemielita T, Hughes JZ, et al. Membrane pressures predict clotting of pediatric continuous renal replacement therapy circuits. Pediatr Nephrol. 2017;32(7):1251-1261.
Villa G, Chelazzi C, Morettini E, et al. Organ dysfunction during continuous veno-venous high cut-off hemodialysis in patients with septic acute kidney injury: a prospective observational study. PLoS One. 2017;12(2):e0172039.
Balgobin S, Morena M, Brunot V, et al. Continuous veno-venous high cut-off hemodialysis compared to continuous veno-venous hemodiafiltration in intensive care unit acute kidney injury patients. Blood Purif. 2018;46(3):248-256.
Boschetti-de-Fierro A, Beck W, Hildwein H, Krause B, Storr M, Zweigart C. Membrane innovation in dialysis. In: Ronco C, editor. Contributions to Nephrology. Basel, Switzerland: S. Karger AG; 2017;100-114.
Maduell F, Rodas L, Broseta JJ, et al. Medium cut-off dialyzer versus eight hemodiafiltration dialyzers: comparison using a global removal score. Blood Purif. 2019;48(2):167-174.
Reque J, Pérez Alba A, Panizo N, Sánchez-Canel JJ, Pascual MJ, Pons PR. Is expanded hemodialysis an option to online hemodiafiltration for small- and middle-sized molecules clearance? Blood Purif. 2019;47(1-3):126-131.
Ronco C, Reis T, Cozzolino M. Rationale for medium cutoff membranes in COVID-19 patients requiring renal replacement therapy. Nephron. 2020;144(11):550-554.
Ronco C, Reis T, Husain-Syed F. Management of acute kidney injury in patients with COVID-19. Lancet Respir Med. 2020;8(7):738-742.
Ronco C, Reis T. Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nat Rev Nephrol. 2020;16(6):308-310.
Nadim MK, Forni LG, Mehta RL, et al. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nat Rev Nephrol. 2020. https://doi.org/10.1038/s41581-020-00356-5
Ronco C, Bagshaw SM, Bellomo R, et al. Extracorporeal blood purification and organ support in the critically ill patient during COVID-19 pandemic: expert review and recommendation. Blood Purif. 2021;50(1):17-27.
Weidhase L, Haussig E, Haussig S, Kaiser T, de Fallois J, Petros S. Middle molecule clearance with high cut-off dialyzer versus high-flux dialyzer using continuous veno-venous hemodialysis with regional citrate anticoagulation: a prospective randomized controlled trial. PLoS One. 2019;14(4):e0215823.
Piechota M, Piechota A. An evaluation of the usefulness of single pass albumin dialysis: key role of dialysate flow rate. Crit Care. 2016;20(1):156.
Bakhsh S, Teoh CW, Harvey EA, Noone DG. Single pass albumin dialysis and plasma exchange for copper toxicity in acute Wilson disease. Case Rep Nephrol Dial. 2019;9(2):55-63.
Jamal J-A, Mueller BA, Choi GYS, Lipman J, Roberts JA. How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy? Diagn Microbiol Infect Dis. 2015;82(1):92-103.
Shaw AR, Mueller BA. Antibiotic dosing in continuous renal replacement therapy. Adv Chronic Kidney Dis. 2017;24(4):219-227.
Lenga I, Hopman WM, O'Connell AJ, Hume F, Wei CCY. Flexitrate regional citrate anticoagulation in continuous venovenous hemodiafiltration: a retrospective analysis. BMC Nephrol. 2019;20(1):452.
Harm S, Falkenhagen D, Hartmann J. Pore size-a key property for selective toxin removal in blood purification. Int J Artif Organs. 2014;37(9):668-678.
Chen J, Han W, Su R, et al. Non-ionic macroporous polystyrene adsorbents for removal of serum toxins in liver failure by hemoperfusion. Artif Cells Nanomed Biotechnol. 2017;45(1):174-183.
La Manna G, Donati G. Coupled plasma filtration adsorption: a multipurpose extracorporeal detoxification therapy. Blood Purif. 2018;46(3):228-238.
Chen J, Cheng G, Chai Y, et al. Preparation of nano-CaCO3/polystyrene nanocomposite beads for efficient bilirubin removal. Colloids Surf B. 2018;161:480-487.
Chen J, Han W, Chen J, et al. High performance of a unique mesoporous polystyrene-based adsorbent for blood purification. Regen Biomater. 2017;4(1):31-37.
Donati G, La Manna G, Cianciolo G, et al. Extracorporeal detoxification for hepatic failure using molecular adsorbent recirculating system: depurative efficiency and clinical results in a long-term follow-up: detoxification and survival using MARS. Artif Organs. 2014;38(2):125-134.
Donati G, Angeletti A, Gasperoni L, et al. Detoxification of bilirubin and bile acids with intermittent coupled plasmafiltration and adsorption in liver failure (HERCOLE study). J Nephrol. 2020. https://doi.org/10.1007/s40620-020-00799-w
Monchi M. Citrate pathophysiology and metabolism. Tranfus Apher Sci. 2017;56(1):28-30.
Khadzhynov D, Dahlinger A, Schelter C, et al. Hyperlactatemia, lactate kinetics and prediction of citrate accumulation in critically ill patients undergoing continuous renal replacement therapy with regional citrate anticoagulation. Crit Care Med. 2017;45(9):e941-e946.
Schneider AG, Journois D, Rimmelé T. Complications of regional citrate anticoagulation: accumulation or overload? Crit Care. 2017;21(1):281.
Tan J-N, Haroon SWP, Mukhopadhyay A, et al. Hyperlactatemia predicts citrate intolerance with regional citrate anticoagulation during continuous renal replacement therapy. J Intensive Care Med. 2019;34(5):418-425.
Mariano F, Morselli M, Holló Z, Agostini F, Stella M, Biancone L. Citrate pharmacokinetics at high levels of circuit citratemia during coupled plasma filtration adsorption. Nephrol Dial Transplant. 2015;30(11):1911-1919.
Hamdi T, Palmer BF. Review of extracorporeal membrane oxygenation and dialysis-based liver support devices for the use of nephrologists. Am J Nephrol. 2017;46(2):139-149.
Bañares R, Nevens F, Larsen FS, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology. 2013;57(3):1153-1162.
Boyle AJ, Sklar MC, McNamee JJ, et al. Extracorporeal carbon dioxide removal for lowering the risk of mechanical ventilation: research questions and clinical potential for the future. Lancet Respir Med. 2018;6(11):874-884.
Bein T, Weber-Carstens S, Goldmann A, et al. Lower tidal volume strategy (≈3 ml/kg) combined with extracorporeal CO2 removal versus ‘conventional’ protective ventilation (6 ml/kg) in severe ARDS: the prospective randomized Xtravent-study. Intensive Care Med. 2013;39(5):847-856.
Combes A, Tonetti T, Fanelli V, et al. Efficacy and safety of lower versus higher CO2 extraction devices to allow ultraprotective ventilation: secondary analysis of the SUPERNOVA study. Thorax. 2019;74(12):1179-1181.
McNamee J, Gillies M, Barrett N, et al. pRotective vEntilation with veno-venouS lung assisT in respiratory failure: A protocol for a multicentre randomised controlled trial of extracorporeal carbon dioxide removal in patients with acute hypoxaemic respiratory failure. J Intensive Care Soc. 2017;18(2):159-169.
Jonckheer J, Spapen H, Debain A, et al. CO2 and O2 removal during continuous veno-venous hemofiltration: a pilot study. BMC Nephrol. 2019;20(1):222.
Feri M. “In vitro comparison of the adsorption of inflammatory mediators by blood purification devices”: a misleading article for clinical practice? Intensive Care Med Exp. 2019;7(1):5.
Villa G, Romagnoli S, De Rosa S, et al. Blood purification therapy with a hemodiafilter featuring enhanced adsorptive properties for cytokine removal in patients presenting COVID-19: a pilot study. Crit Care. 2020;24(1):605.
Pomarè Montin D, Ankawi G, Lorenzin A, Neri M, Caprara C, Ronco C. Biocompatibility and cytotoxic evaluation of new sorbent cartridges for blood hemoperfusion. Blood Purif. 2018;46(3):187-195.
Honoré PM, De Bels D, Barreto Gutierrez L, Spapen HD. Hemoadsorption therapy in the critically ill: solid base but clinical haze. Ann Intensive Care. 2019;9(1):22.
Brouwer WP, Duran S, Kuijper M, Ince C. Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study. Crit Care. 2019;23(1):317.
Alharthy A, Faqihi F, Memish ZA, et al. Continuous renal replacement therapy with the addition of CytoSorb® cartridge in critically ill patients with COVID-19 plus acute kidney injury: a case-series. Artif Organs. 2020. https://doi.org/10.1111/aor.13864
Rieder M, Duerschmied D, Zahn T, et al. Cytokine adsorption in severe acute respiratory failure requiring veno-venous extracorporeal membrane oxygenation. ASAIO J. 2020. https://doi.org/10.1097/MAT.0000000000001302
Rugg C, Klose R, Hornung R, et al. Hemoadsorption with CytoSorb in septic shock reduces catecholamine requirements and in-hospital mortality: a single-center retrospective ‘genetic’ matched analysis. Biomedicines. 2020;8(12):539.
Lipcsey M, Tenhunen J, Sjölin J, et al. Abdominal Septic Shock-Endotoxin Adsorption Treatment (ASSET)-endotoxin removal in abdominal and urogenital septic shock with the Alteco® LPS Adsorber: study protocol for a double-blinded, randomized placebo-controlled trial. Trials. 2016;17(1):587.
Lipcsey M, Tenhunen J, Pischke SE, et al. Endotoxin removal in septic shock with the Alteco® LPS adsorber was safe but showed no benefit compared to placebo in the double-blind randomized controlled trial-the asset study. Shock. 2019. https://doi.org/10.1097/SHK.0000000000001503
Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301(23):2445.
The ABDOMIX Group, Payen DM, Guilhot J, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015;41(6):975-984.
Sirivongrangson P, Kulvichit W, Payungporn S, et al. Endotoxemia and circulating bacteriome in severe COVID-19 patients. Intensive Care Critical Care Med. 2020. https://doi.org/10.1101/2020.05.29.20109785
Belančić A. Gut microbiome dysbiosis and endotoxemia-additional pathophysiological explanation for increased COVID-19 severity in obesity. Obes Med. 2020;20:100302.
Abdul-Aziz MH, Roberts JA. Antibiotic dosing during extracorporeal membrane oxygenation: does the system matter? Curr Opin Anesthesiol. 2020;33(1):71-82.
Schmidt JJ, Eden G, Seffer M-T, Winkler M, Kielstein JT. In vitro elimination of anti-infective drugs by the Seraph® 100 Microbind® affinity blood filter. Clin Kidney J. 2020;13(3):421-424. https://doi.org/10.1093/ckj/sfaa063
Shimokawa K, Takakuwa R, Taya K, et al. Adsorption of various antimicrobial agents to endotoxin removal polymyxin-B immobilized fiber (Toraymyxin®). Colloids Surf B. 2012;90:58-61.
Poli EC, Rimmelé T, Schneider AG. Hemoadsorption with CytoSorb®. Intensive Care Med. 2019;45(2):236-239.
Tian Q, Gomersall CD, Ip M, Joynt GM. Effect of preexposure to aminoglycosides on in vitro adsorption of amikacin by polyacrylonitrile hemofilters. Antimicrob Agents Chemother. 2011;55(7):3641-3642.
Allawati H, Dallas L, Nair S, Palmer J, Thaikandy S, Hutchison C. A pharmacokinetic study comparing the clearance of vancomycin during haemodialysis using medium cut-off membrane (Theranova) and high-flux membranes (Revaclear). Toxins. 2020;12(5):317.
Brock L. The importance of environmental conditions, especially temperature, in the operating room and intensive care ward. Br J Surg. 1975;62(4):253-258.
Bell M, Ronco C, Hansson F, Broman M. Hypothermia during CRRT, a comparative analysis. Acta Anaesthesiol Scand. 2020;64(8):1162-1166.
Lascarrou J-B, Merdji H, Le Gouge A, et al. Targeted temperature management for cardiac arrest with nonshockable rhythm. N Engl J Med. 2019;381(24):2327-2337.
Calabró L, Bougouin W, Cariou A, et al. Effect of different methods of cooling for targeted temperature management on outcome after cardiac arrest: a systematic review and meta-analysis. Crit Care. 2019;23(1):285.
Redant S, De Bels D, Honoré PM. Rationale of blood purification in the post-resuscitation syndrome following out-of-hospital cardiac arrest: a narrative review. Blood Purif. 2021;1-8. https://doi.org/10.1159/000510127